Back to Search
Start Over
POSC77 Incorporating Possibility of Cure into Cost Utility Analysis for Nivolumab in Adjuvant Treatment of Resected Stage III/IV Melanoma in France.
- Source :
-
Value in Health . 2022 Supplement, Vol. 25 Issue 1, pS101-S101. 1p. - Publication Year :
- 2022
- Subjects :
- *COST analysis
*NIVOLUMAB
*MELANOMA
*POSSIBILITY
*THERAPEUTICS
Subjects
Details
- Language :
- English
- ISSN :
- 10983015
- Volume :
- 25
- Issue :
- 1
- Database :
- Academic Search Index
- Journal :
- Value in Health
- Publication Type :
- Academic Journal
- Accession number :
- 154761778
- Full Text :
- https://doi.org/10.1016/j.jval.2021.11.482